Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Double-Blind Placebo-Controlled Study of DS-1211b in Pseudoxanthoma Elasticum
2022-000676-19Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pseudoxanthoma elasticum (PXE) comparing DS-1211b arm with Placebo arm (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jun 2022; status: completed.
02
Drugs
DL-404
03
Conditions
pseudoxanthoma elasticum (PXE)
Beyond the preview
Go deeper on 2022-000676-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000676-19.